Scilex Holding Co Stock Price, News & Analysis

Scilex Holding Company (SCLX) announced a publication highlighting GLOPERBA's dosing adjustments in a peer-reviewed journal. GLOPERBA is the first liquid oral colchicine for gout flare prophylaxis, enabling precision dosing for patients with renal impairment. The study reveals that patients with renal issues taking standard colchicine formulations often receive sub-optimal or excessive doses. The research demonstrates that GLOPERBA's liquid format allows for more precise dosing: 0.48 mg for moderate renal impairment and 0.3 mg for severe renal impairment, leading to better therapeutic outcomes. This is particularly significant as over 70% of gout patients have comorbid conditions requiring dose adjustments.

Scilex Holding Company (NASDAQ: SCLX) presented a post-hoc analysis of their C.L.E.A.R. trial at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP). The analysis focused on interpreting the clinical meaningfulness of SP-102 (SEMDEXA™) for treating lumbosacral radicular pain (LRP).

The results demonstrated that SP-102 showed clinically meaningful separation from placebo across multiple endpoints, including NPRS Responder Analyses, ODI, and BPI Pain Interference. The effectiveness was particularly notable in the modified intent-to-treat (mITT) population. When compared to other marketed analgesics for chronic low back pain and TSIs, SP-102's standard effect size showed promising results.

The drug was specifically formulated to provide a safer alternative to current off-label products that carry warnings of potentially dangerous and life-threatening adverse events. The overall benefit-risk profile suggests SP-102 could be a safe and effective treatment option for LRP patients.

Scilex Holding Company (NASDAQ: SCLX) announced it will present a post-hoc analysis of their C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) from May 15-17, 2025 in Orlando, FL. The presentation will focus on interpreting the clinical meaningfulness of safety and efficacy data for SP-102 (SEMDEXA™) in treating lumbosacral radicular pain (LRP).

The poster presentation will be displayed throughout the meeting and will be accessible via the conference app. Additionally, it will be published in the Pain Physician journal. The research was conducted by a team of authors including Miller AM, Knezevic NN, Nalamachu S, and others.

Scilex Holding Company has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, trading under the symbol SCLX, met the crucial requirement of maintaining a minimum closing bid price of $1.00 per share for at least ten consecutive trading days, achieving this milestone on April 30, 2025.

As a result, Scilex will continue trading on the Nasdaq Capital Market under the symbols "SCLX" for common stock and "SCLXW" for public warrants. The company specializes in non-opioid pain management products, focusing on treatments for acute and chronic pain, along with neurodegenerative and cardiometabolic diseases.

This compliance achievement ensures Scilex maintains its position on the Nasdaq exchange, providing stability for this revenue-generating pharmaceutical company that develops and commercializes innovative pain management solutions.

Scilex Holding Company (SCLX) has announced a change in the record date for its previously declared dividend of preferred stock. The dividend, which is exchangeable for up to 10% of Scilex's ownership interest in its wholly owned subsidiary Semnur Pharmaceuticals, will now have a record date of May 2, 2025, instead of the previously announced April 11, 2025.

The payment date will be determined by subsequent Board resolutions and will occur within 60 days following the new record date. Scilex, which focuses on non-opioid pain management products for acute and chronic pain, neurodegenerative and cardiometabolic disease treatments, maintains its commitment to delivering value to its stockholders and securityholders through this dividend distribution.

Scilex Holding Company (NASDAQ: SCLX) has received FDA approval for Orphan Drug Designation for colchicine in treating pericarditis. Their product Gloperba®, the first and only liquid oral colchicine, is currently indicated for gout flare prophylaxis in adults.

Gloperba® is administered like cough syrup with a dosage of 0.6mg per 5ml, offering advantages for patients who struggle with pills. The liquid format enables more flexible dosing and titration options, particularly beneficial for gout patients with renal or hepatic impairment.

The Orphan Drug Designation applies to conditions affecting fewer than 200,000 individuals in the US. If approved, it would grant seven years of market exclusivity for treating pericarditis, an inflammatory condition of the heart's protective membrane.

Scilex Holding Company (NASDAQ: SCLX) has received approval from Health Canada for ELYXYB®, their ready-to-use oral solution for acute migraine treatment. ELYXYB® is the only FDA-approved oral solution in its category and demonstrates pain relief in as fast as 15 minutes, with significant relief compared to placebo within 45 minutes in approximately 50% of patients.

The Canadian market represents a significant opportunity, with over 2.7 million Canadians affected by migraines and the migraine therapeutics market projected to reach $400 million by 2025. The drug, which is manufactured in Canada, offers a first-line treatment option with potentially lower gastrointestinal side effects compared to other NSAIDs.

Scilex Holding Company (SCLX) has announced a 1-for-35 reverse stock split effective April 15, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The split will reduce outstanding shares from approximately 243 million to 6.9 million.

The company's common stock will continue trading on Nasdaq under the symbol 'SCLX' with a new CUSIP number (80880W 205). No fractional shares will be issued; instead, affected stockholders will receive cash payments. The split will also apply to outstanding warrants, Series A Preferred Stock, convertible notes, and stock options, with proportionate adjustments to exercise and conversion prices.

This decision follows stockholder approval at a special meeting on March 19, 2025, where the board received authority to select a ratio between 1-for-14 and 1-for-50 shares.

Scilex Holding Company (NASDAQ: SCLX) has appealed a lower court decision to the U.S. Court of Appeals for the Federal Circuit regarding its patent infringement lawsuit against Aveva Drug Delivery Systems. The case stems from May 2022, when Aveva submitted an Abbreviated New Drug Application (ANDA) to the FDA with a Paragraph IV notice concerning Scilex's ZTlido patents.

Initially filed in June 2022 at the U.S. District Court for the Southern District of Florida, the lawsuit alleged infringement of Scilex's Orange Book-listed patents for ZTlido. Following a trial in July 2024, the District Court ruled that Aveva's proposed product did not infringe Scilex's patents. The company is now vigorously pursuing an appellate review, with CEO Jaisim Shah expressing confidence in the strength of ZTlido's intellectual property portfolio.